AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
On August 14, 2025,
(WDAY) closed with a 0.52% decline, trading at a volume of $720 million—ranking 130th in daily trading activity. The stock’s performance followed news of its acquisition of Flowise, a low-code platform for AI agent development.The acquisition, announced on the same day, aims to enhance Workday’s AI capabilities by integrating Flowise’s intuitive visual builder and open-source infrastructure. Flowise’s platform, which supports end-to-end AI development from prototyping to deployment, has gained traction across industries with over 42,000 GitHub stars and millions of workflows processed. Workday emphasized that the integration will accelerate innovation for customers in HR and finance, enabling faster deployment of customized AI agents while maintaining transparency and scalability.
Workday’s CTO Peter Bailis highlighted the strategic value of Flowise’s open-source foundation, stating it will empower users to build and manage AI agents with greater control. Flowise CEO Henry Heng noted the acquisition aligns with the platform’s mission to democratize AI development, reducing reliance on technical expertise. The move also reinforces Workday’s commitment to responsible AI through features like human-in-the-loop checkpoints and secure deployment options.
The strategy of buying the top 500 stocks by daily trading volume and holding them for one day from 2022 to now delivered moderate returns. The CAGR was 6.98%, with a maximum drawdown of 15.59% during the backtest period. The strategy demonstrated steady growth over time, making it a robust choice for investors seeking consistent returns. However, the significant drawdown in mid-2023 highlights the importance of risk management in high-volume trading strategies.

Market Watch column provides a thorough analysis of stock market fluctuations and expert ratings.

Dec.31 2025

Dec.31 2025

Dec.30 2025

Dec.30 2025

Dec.29 2025
Daily stocks & crypto headlines, free to your inbox
Comments
No comments yet